Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Evaluation of an injection depot formulation of buprenorphine: placebo comparison.

Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE.

Addiction. 2004 Nov;99(11):1439-49.

PMID:
15500597
2.

Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.

Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, Kerrigan JH, Bigelow GE.

Drug Alcohol Depend. 2004 Jan 7;73(1):11-22.

PMID:
14687955
3.

Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.

Strain EC, Bigelow GE, Liebson IA, Stitzer ML.

JAMA. 1999 Mar 17;281(11):1000-5.

PMID:
10086434
4.

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.

Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, Stitzer ML.

Drug Alcohol Depend. 1997 Apr 14;45(1-2):81-91.

PMID:
9179510
5.

The effects of buprenorphine in buprenorphine-maintained volunteers.

Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE.

Psychopharmacology (Berl). 1997 Feb;129(4):329-38.

PMID:
9085402
6.

Opioid antagonist effects of dezocine in opioid-dependent humans.

Strain EC, Preston KL, Liebson IA, Bigelow GE.

Clin Pharmacol Ther. 1996 Aug;60(2):206-17.

PMID:
8823239
7.

Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

J Clin Psychopharmacol. 1996 Feb;16(1):58-67.

PMID:
8834420
8.

Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.

Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML.

J Pharmacol Exp Ther. 1996 Feb;276(2):449-59.

PMID:
8632309
9.

Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.

Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1995 Nov;40(1):27-35.

PMID:
8746921
10.

A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.

Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1995 Nov;40(1):17-25.

PMID:
8746920
11.

Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.

Strain EC, Preston KL, Liebson IA, Bigelow GE.

J Pharmacol Exp Ther. 1995 Feb;272(2):628-38.

PMID:
7853176
12.

Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

Psychopharmacology (Berl). 1994 Dec;116(4):401-6.

PMID:
7701040
13.

Comparison of buprenorphine and methadone in the treatment of opioid dependence.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

Am J Psychiatry. 1994 Jul;151(7):1025-30.

PMID:
8010359
14.

Outcome after methadone treatment: influence of prior treatment factors and current treatment status.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1994 Jun;35(3):223-30.

PMID:
7956752
15.

Precipitated withdrawal by pentazocine in methadone-maintained volunteers.

Strain EC, Preston KL, Liebson IA, Bigelow GE.

J Pharmacol Exp Ther. 1993 Nov;267(2):624-34.

PMID:
7504098
16.

Methadone dose and treatment outcome.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1993 Sep;33(2):105-17.

PMID:
8261875
17.

Dose-response effects of methadone in the treatment of opioid dependence.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

Ann Intern Med. 1993 Jul 1;119(1):23-7.

PMID:
8498759
18.

Buprenorphine alone and in combination with naloxone in non-dependent humans.

Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1992 Aug;30(3):263-74.

PMID:
1396108
19.

Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.

Strain EC, Preston KL, Liebson IA, Bigelow GE.

J Pharmacol Exp Ther. 1992 Jun;261(3):985-93.

PMID:
1376362
20.

Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.

Preston KL, Liebson IA, Bigelow GE.

J Pharmacol Exp Ther. 1992 Apr;261(1):62-71.

PMID:
1373189
21.

Evaluation of the abuse potential of the novel analgesic flupirtine maleate.

Preston KL, Funderburk FR, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1991 Mar;27(2):101-13.

PMID:
2055157
22.

Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone.

Wright C, Bigelow GE, Stitzer ML, Liebson IA.

Drug Alcohol Depend. 1991 Mar;27(2):139-48.

PMID:
1647293
23.

Discrimination of butorphanol and nalbuphine in opioid-dependent humans.

Preston KL, Bigelow GE, Liebson IA.

Pharmacol Biochem Behav. 1990 Nov;37(3):511-22.

PMID:
1708145
24.

Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hours postmorphine.

Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA.

Pharmacol Biochem Behav. 1990 Jun;36(2):393-9.

PMID:
2356213
25.

Effects of sublingually given naloxone in opioid-dependent human volunteers.

Preston KL, Bigelow GE, Liebson IA.

Drug Alcohol Depend. 1990 Feb;25(1):27-34.

PMID:
2323306
26.

Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect.

Bickel WK, Bigelow GE, Preston KL, Liebson IA.

J Pharmacol Exp Ther. 1989 Dec;251(3):1053-63.

PMID:
2481029
27.

Reinforcing effects of caffeine in coffee and capsules.

Griffiths RR, Bigelow GE, Liebson IA.

J Exp Anal Behav. 1989 Sep;52(2):127-40.

28.

Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.

Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA.

J Pharmacol Exp Ther. 1989 Aug;250(2):485-91.

PMID:
2760839
29.

Drug discrimination in human postaddicts: agonist-antagonist opioids.

Preston KL, Bigelow GE, Bickel WK, Liebson IA.

J Pharmacol Exp Ther. 1989 Jul;250(1):184-96.

PMID:
2473187
30.

Antagonist effects of nalbuphine in opioid-dependent human volunteers.

Preston KL, Bigelow GE, Liebson IA.

J Pharmacol Exp Ther. 1989 Mar;248(3):929-37.

PMID:
2467983
31.

Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.

Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA.

J Pharmacol Exp Ther. 1989 Jan;248(1):127-34.

PMID:
2913267
32.

Relative abuse liability of lorazepam and diazepam: an evaluation in 'recreational' drug users.

Funderburk FR, Griffiths RR, McLeod DR, Bigelow GE, Mackenzie A, Liebson IA, Nemeth-Coslett R.

Drug Alcohol Depend. 1988 Dec;22(3):215-22.

PMID:
3234245
33.

Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use.

Iguchi MY, Stitzer ML, Bigelow GE, Liebson IA.

Drug Alcohol Depend. 1988 Oct;22(1-2):1-7.

PMID:
2906863
34.

Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE.

J Pharmacol Exp Ther. 1988 Oct;247(1):47-53.

PMID:
2459370
35.

Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.

Preston KL, Bigelow GE, Liebson IA.

J Pharmacol Exp Ther. 1988 Aug;246(2):441-8.

PMID:
2457074
36.

Acute physical dependence in man: effects of naloxone after brief morphine exposure.

Bickel WK, Stitzer ML, Liebson IA, Bigelow GE.

J Pharmacol Exp Ther. 1988 Jan;244(1):126-32.

PMID:
3335995
37.

A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE.

Clin Pharmacol Ther. 1988 Jan;43(1):72-8.

PMID:
3275523
38.

Buprenorphine and naloxone alone and in combination in opioid-dependent humans.

Preston KL, Bigelow GE, Liebson IA.

Psychopharmacology (Berl). 1988;94(4):484-90.

PMID:
2453895
39.

Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.

Preston KL, Bigelow GE, Bickel W, Liebson IA.

J Pharmacol Exp Ther. 1987 Dec;243(3):1002-9.

PMID:
2447262
40.

Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.

Preston KL, Bigelow GE, Liebson IA.

J Pharmacol Exp Ther. 1987 Mar;240(3):900-10.

PMID:
3559982
41.

A clinical trial of buprenorphine: I. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties.

Bickel WK, Johnson RE, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR.

NIDA Res Monogr. 1987;76:182-8. No abstract available.

PMID:
2449618
42.

Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.

Preston KL, Bigelow GE, Liebson IA.

NIDA Res Monogr. 1987;76:157-61. No abstract available.

PMID:
2449617
43.

Abuse liability assessment of buprenorphine-naloxone combinations.

Bigelow GE, Preston KL, Liebson IA.

NIDA Res Monogr. 1987;76:145-9. No abstract available.

PMID:
2449616
44.

Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients.

Stitzer ML, Bickel WK, Bigelow GE, Liebson IA.

Drug Alcohol Depend. 1986 Dec;18(4):341-8.

PMID:
3816530
45.

Human coffee drinking: reinforcing and physical dependence producing effects of caffeine.

Griffiths RR, Bigelow GE, Liebson IA.

J Pharmacol Exp Ther. 1986 Nov;239(2):416-25.

PMID:
3772801
46.

Contingent methadone delivery: effects on illicit-opiate use.

Higgins ST, Stitzer ML, Bigelow GE, Liebson IA.

Drug Alcohol Depend. 1986 Jul;17(4):311-22.

PMID:
3757767
47.

Human coffee drinking: manipulation of concentration and caffeine dose.

Griffiths RR, Bigelow GE, Liebson IA, O'Keeffe M, O'Leary D, Russ N.

J Exp Anal Behav. 1986 Mar;45(2):133-48.

48.

Naloxone-precipitated withdrawal in humans after acute morphine administration.

Bickel WK, Stitzer ML, Wazlavek BE, Liebson IA.

NIDA Res Monogr. 1986;67:349-54. No abstract available.

PMID:
3092089
49.

Three-way drug discrimination in post-addict volunteers: hydromorphone, pentazocine, and saline.

Bickel WK, Preston KL, Bigelow GE, Liebson IA.

NIDA Res Monogr. 1986;67:177-83. No abstract available.

PMID:
2427951
50.

Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification.

Preston KL, Bigelow GE, Liebson IA.

Clin Pharmacol Ther. 1985 Aug;38(2):219-27.

PMID:
2410178

Supplemental Content

Loading ...
Support Center